Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“DESTINY-Breast09: Enhertu plus pertuzumab shows superior PFS vs THP in 1L HER2+ mBC — first regimen in over a decade to outperform SoC.
Data to be presented at an upcoming medical meeting.”
